Damnacanthal 是一种从 Morinda citrifolia 根中分离得到的蒽醌,作为强效且选择性的 p56lck 酪氨酸激酶活性抑制剂,天然 Damnacanthal 抑制 p56lck 自磷酸化和外源底物磷酸化的 IC50 分别为 46 nM 和 220 nM,它也是一种具有抗癌活性的有效凋亡诱导剂,并在小鼠中具有抗炎作用,还可用于缓解疼痛的研究,同时对白色念珠菌具有抗真菌活性。
产品编号: MS-E45617 纯度: 99.40% CAS No.: 477-84-9 分子式: C16H10O5 分子量: 282.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Damnacanthal 是一种从 Morinda citrifolia 根中分离得到的蒽醌,作为强效且选择性的 p56lck 酪氨酸激酶活性抑制剂,天然 Damnacanthal 抑制 p56lck 自磷酸化和外源底物磷酸化的 IC50 分别为 46 nM 和 220 nM,它也是一种具有抗癌活性的有效凋亡诱导剂,并在小鼠中具有抗炎作用,还可用于缓解疼痛的研究,同时对白色念珠菌具有抗真菌活性。

生物实验数据

生物活性 Damnacanthal is an anthraquinone isolated from the roots of Morinda citrifolia and acts as a potent and selective inhibitor of p56lck tyrosine kinase activity; natural Damnacanthal inhibits p56lck autophosphorylation and phosphorylation of exogenous substrates with IC50 values of 46 nM and 220 nM, respectively, and it is also a potent apoptosis inducer with anticancer activity, exhibits anti-inflammatory effects in mice, can be used in pain relief research, and possesses antifungal activity against Candida albicans.
IC50 & Target Phosphorylation of exogenous substrates by p56lck:220 nM (IC50), p56lck autophosphorylation:46 nM (IC50)
体外研究
(In Vitro)

Damnacanthal has > 100-fold selectivity for p56lck over the serine/threonine kinases, protein kinase A and protein kinase C, and > 40-fold selectivity for p56lck over four receptor tyrosine kinases. Damnacanthal also demonstrates modest (7-20-fold), but highly statistically significant, selectivity for p56lck over the homologous enzymes p60src and p59fyn.
Damnacanthal (0.1-100 μM; 1-4 days; HCT-116 and SW480 cells) treatment results in a significant reduction of cell proliferation in a concentration- and time-dependent manner.
Damnacanthal (1-50 μM; 72 hours; HCT-116 cells) treatment results in a significant enrichment in the number of cells in the S/G1 and G2/G1 phases at concentration of 50 μM.
Damnacanthal (10 μM; 24 hours; HCT-116 cells) treatment significantly increases caspase 3/7 activity. Damnacanthal-induced apoptosis.
Damnacanthal (0.1-10 μM; 24 hours; HCT-116 cells) treatment induces NAG-1 expression in HCT-116 cells. Cyclin D1 expression is reduced at 10 μM of Damnacanthal, whereas p21 and p53 does not alter their expression. PARP cleavage is seen at 10 μM Damnacanthal treatment only in HCT-116 cells, where NAG-1 is induced.
Damnacanthal treatment for 2 weeks shows significant decreasing colony number in HCT-116 cells in a concentration-dependent manner. Damnacanthal-treated cells show a dramatic inhibition of clonogenic capacity. Damnacanthal-treated (1-50 μM; 48 hours) cells significantly inhibits the migration of HCT-116 cells in a concentration-dependent manner.

Cell Proliferation Assay

Cell Line: HCT-116 and SW480 cells
Concentration: 0.1 μM, 1 μM, 10 μM, 100 μM
Incubation Time: 1, 2, and 4 days
Result: Resulted in a significant reduction of cell proliferation in a concentration- and time-dependent manner.

Cell Cycle Analysis

Cell Line: HCT-116 cells
Concentration: 1 μM, 10 μM and 50 μM
Incubation Time: 72 hours
Result: Resulted in a significant enrichment in the number of cells in the S/G1 and G2/G1 phases at concentration of 50 μM.

Apoptosis Analysis

Cell Line: HCT-116 cells
Concentration: 10 μM
Incubation Time: 24 hours
Result: Significantly increased caspase 3/7 activity.

Western Blot Analysis

Cell Line: HCT-116 cells
Concentration: 0.1 μM, 1 μM and 10 μM
Incubation Time: 24 hours
Result: NAG-1 was induced in HCT-116 cells in a dose- and time-dependent manner. Cyclin D1 expression was reduced at 10 μM.
体内研究
(In Vivo)

Damnacanthal (10-100 mg/kg; oral administration; for 10-300 minutes; male ddY mice) treatment exhibits a significant antinociceptive effect in a dose-dependent manner in the formalin test. Administration of damnacanthal (100 mg/kg) shows significant inhibition of histamine-induced paw edema.

Animal Model: Male ddY mice (5-6 weeks) injected with formalin or Histamine
Dosage: 10 mg/kg, 30 mg/kg and 100 mg/kg
Administration: Oral administration; for 10 minutes, 30 minutes, 60 minutes or 300 minutes
Result: Significantly reduced the growth of human lung tumor without acute toxicity.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 282.25
分子式 C16H10O5
CAS No. 477-84-9

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 5 mg/mL (17.71 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.5430 mL17.7148 mL35.4296 mL88.5740 mL
5 mM0.7086 mL3.5430 mL7.0859 mL17.7148 mL
10 mM0.3543 mL1.7715 mL3.5430 mL8.8574 mL
15 mM0.2362 mL1.1810 mL2.3620 mL5.9049 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础